## **United States Oncology**



## Historical to Current FTE Trend Analysis/Interactive Dashboard

2015-2019 Edition

An interactive tool for companies competing, or poised to compete, in the Oncology/Hematology space including the Biomarker/Pathology and CAR-T areas. This dashboard provides an opportunity to confidently sort and compare Sales FTEs down to approximately 70 indications across marketed brands, as well as deployment of other Commercial FTEs.

Data for each company and/or year can be sorted and compared in terms of:

- Number of Commercial Oncology FTEs across multiple disciplines
  - Sales Representatives
  - Key Account Personnel
  - Oncology Nurse Educators
- Number of Sales FTEs by product/brand
- Number of Sales FTEs by approximately 70 indications
  - Solid Tumor Types
- Number of Sales FTEs by indication and company
- Number of Biomarker/Pathology FTEs by company across the following disciplines
  - Sales Representatives
  - Marketing
- Number of CAR-T FTEs by company across the following disciplines
  - Sales Representatives
  - Marketing
- Top 10 lists by each year in terms of
  - Companies
  - Products
- Major FDA product approvals and label expansions

## For more information, please contact

Joyce Wedemeyer at joyce.wedemeyer@strategicreports.com or by phone at 610-370-2906

## **PharmaForce International Inc.**

Insightful Intelligence with a Global Reach 2645 Perkiomen Avenue • Reading, PA 19606 (610) 370-5640 • Fax (610) 370-5641 www.pharmaforce.biz

Field Medical

Marketing

• Liquid Tumor Types

Field Reimbursement

• Field Medical

Field Medical

Indications